“Revolutionary New Drug for Hypertrophic Cardiomyopathy: Mavacamten”

2023-05-21 06:32:41

Cardiology
–

New family of drugs

The EMA has given the ‘yes’ to mavacamten, the first drug for hypertrophic cardiomyopathy, which affects 1 in 500 people and is the leading cause of sudden death in young people.

Treatment with myosin inhibitors requires periodic monitoring of the patient with echocardiography. Photo: SHUTTERSTOCK

1684669473
#Targeted #therapy #arrives #hypertrophic #cardiomyopathy